Theravance Biopharma (TBPH) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Theravance Biopharma Revenue Highlights

Latest Revenue (Y)

$57.42M

Latest Revenue (Q)

$14.26M

Main Segment (Y)

YUPELRI Monotherapy

Main Geography (Y)

United States

Theravance Biopharma Revenue by Period

Theravance Biopharma Revenue by Year

Date	Revenue	Change
2023-12-31	$57.42M	11.84%
2022-12-31	$51.35M	-7.17%
2021-12-31	$55.31M	-23.03%
2020-12-31	$71.86M	-2.12%
2019-12-31	$73.41M	21.61%
2018-12-31	$60.37M	292.37%
2017-12-31	$15.39M	-68.37%
2016-12-31	$48.65M	15.48%
2015-12-31	$42.13M	260.42%
2014-12-31	$11.69M	5071.68%
2013-12-31	$226.00K	-99.83%
2012-12-31	$130.15M	-

Theravance Biopharma generated $57.42M in revenue during NA 2023, up 11.84% compared to the previous quarter, and up 95.12% compared to the same period a year ago.

Theravance Biopharma Revenue by Quarter

Date	Revenue	Change
2024-06-30	$14.26M	-1.70%
2024-03-31	$14.50M	-17.43%
2023-12-31	$17.57M	11.93%
2023-09-30	$15.69M	14.14%
2023-06-30	$13.75M	31.99%
2023-03-31	$10.42M	-28.89%
2022-12-31	$14.65M	17.65%
2022-09-30	$12.45M	12.68%
2022-06-30	$11.05M	-16.26%
2022-03-31	$13.20M	-11.70%
2021-12-31	$14.95M	13.27%
2021-09-30	$13.19M	2.17%
2021-06-30	$12.91M	-9.42%
2021-03-31	$14.26M	-23.88%
2020-12-31	$18.73M	2.59%
2020-09-30	$18.26M	21.65%
2020-06-30	$15.01M	-24.44%
2020-03-31	$19.86M	-32.67%
2019-12-31	$29.50M	137.38%
2019-09-30	$12.43M	-52.48%
2019-06-30	$26.15M	389.88%
2019-03-31	$5.34M	-66.08%
2018-12-31	$15.74M	22.58%
2018-09-30	$12.84M	-45.31%
2018-06-30	$23.48M	182.20%
2018-03-31	$8.32M	84.25%
2017-12-31	$4.51M	5.61%
2017-09-30	$4.28M	21.83%
2017-06-30	$3.51M	13.67%
2017-03-31	$3.09M	-45.77%
2016-12-31	$5.69M	-70.16%
2016-09-30	$19.07M	248.66%
2016-06-30	$5.47M	-70.28%
2016-03-31	$18.41M	372.90%
2015-12-31	$3.89M	-63.61%
2015-09-30	$10.70M	49.96%
2015-06-30	$7.13M	-65.03%
2015-03-31	$20.40M	1323.66%
2014-12-31	$1.43M	-77.38%
2014-09-30	$6.34M	113.05%
2014-06-30	$2.97M	214.71%
2014-03-31	$945.00K	440.00%
2013-12-31	$175.00K	629.17%
2013-09-30	$24.00K	380.00%
2013-06-30	$5.00K	-77.27%
2013-03-31	$22.00K	-

Theravance Biopharma generated $14.26M in revenue during Q2 2024, up -1.70% compared to the previous quarter, and up 136.85% compared to the same period a year ago.

Theravance Biopharma Revenue Breakdown

Theravance Biopharma Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
YUPELRI Monotherapy	$77.34M	$19.50M	-	-	-
Collaboration revenue	$57.21M	$48.65M	-	-	-
Licensing revenue	-	$2.50M	-	-	-
Viatris collaboration agreement	-	$48.62M	$43.85M	-	-
Collaborative revenue	-	-	$11.46M	-	-
Co Promote Agreement	-	-	-	$43.89M	$13.66M
Collaborative Arrangement Revenue	-	-	-	$26.46M	$31.25M
License	-	-	-	$1.50M	$28.50M

Theravance Biopharma's latest annual revenue breakdown by segment (product or service), as of Dec 23: YUPELRI Monotherapy (57.48%), and Collaboration revenue (42.52%).

Quarterly Revenue by Product

Product/Service	Sep 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Collaboration revenue	$16.87M	$14.50M	$6.00K	$6.00K	$5.00K	$6.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
YUPELRI Monotherapy	$21.77M	$19.33M	$21.23M	$19.30M	$16.40M	$18.70M	$17.20M	$15.30M	-	-	-	-	-	-	-	-	-	-	-	-
Viatris collaboration agreement	-	-	-	$13.74M	$10.41M	$14.61M	$12.45M	$10.88M	$10.69M	$12.13M	$10.40M	-	-	-	-	-	-	-	-	-
Licensing revenue	-	-	-	-	-	-	-	-	$2.50M	-	-	-	-	-	-	-	-	-	-	-
Collaborative revenue	-	-	-	-	-	-	-	-	$9.00K	$2.81M	$2.80M	-	-	-	-	-	-	-	-	-
Nebulized T D4208	-	-	-	-	-	-	-	-	-	-	-	$160.00M	$160.00M	-	-	-	-	-	-	-
Collaborative Arrangement Revenue	-	-	-	-	-	-	-	-	-	-	-	$1.98M	$3.87M	$7.08M	$7.26M	$5.49M	$6.63M	$9.58M	$8.84M	$7.65M
Future Potential Combination Products	-	-	-	-	-	-	-	-	-	-	-	$45.00M	$45.00M	-	-	-	-	-	-	-
Co Promote Agreement	-	-	-	-	-	-	-	-	-	-	-	$10.93M	$10.38M	$11.65M	$11.00M	$9.52M	$11.73M	$9.91M	$3.59M	-
License	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$1.50M	$10.00M	-	$18.50M

Theravance Biopharma's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: YUPELRI Monotherapy (56.34%), and Collaboration revenue (43.66%).

Theravance Biopharma Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
United States	$57.20M	$51.12M	$55.27M	-	-
Europe	$223.00K	$222.00K	$38.00K	$1.54M	$18.65M
U	-	-	-	$70.32M	$54.76M

Theravance Biopharma's latest annual revenue breakdown by geography, as of Dec 23: United States (99.61%), and Europe (0.39%).

Theravance Biopharma Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
OVID	Ovid Therapeutics	$391.69M	$173.00K
CTMX	CytomX Therapeutics	$101.21M	$33.43M
TBPH	Theravance Biopharma	$57.42M	$14.26M
ASMB	Assembly Biosciences	$7.16M	$6.84M
CNTB	Connect Biopharma	-	-
NXTC	NextCure	-	-
TIL	Instil Bio	-	-
GRPH	LENZ Therapeutics	-	-
NLTX	Neurogene	-	-
ACHL	Achilles Therapeutics	-	-
SNSE	Sensei Biotherapeutics	-	-
MACK	Merrimack Pharmaceuticals	-	-
NUVB	Nuvation Bio	-	$727.00K

TBPH Revenue FAQ

What is Theravance Biopharma’s yearly revenue?

Theravance Biopharma's yearly revenue for 2023 was $57.42M, representing an increase of 11.84% compared to 2022. The company's yearly revenue for 2022 was $51.35M, representing a decrease of -7.17% compared to 2021. TBPH's yearly revenue for 2021 was $55.31M, representing a decrease of -23.03% compared to 2020.

What is Theravance Biopharma’s quarterly revenue?

Theravance Biopharma's quarterly revenue for Q2 2024 was $14.26M, a -1.70% decrease from the previous quarter (Q1 2024), and a 3.69% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $14.5M, a -17.43% decrease from the previous quarter (Q4 2023), and a 39.22% increase year-over-year (Q1 2023). TBPH's quarterly revenue for Q4 2023 was $17.56M, a 11.93% increase from the previous quarter (Q3 2023), and a 19.91% increase year-over-year (Q4 2022).

What is Theravance Biopharma’s revenue growth rate?

Theravance Biopharma's revenue growth rate for the last 3 years (2021-2023) was 3.82%, and for the last 5 years (2019-2023) was -21.78%.

What are Theravance Biopharma’s revenue streams?

Theravance Biopharma's revenue streams in c 23 are YUPELRI Monotherapy, and Collaboration revenue. YUPELRI Monotherapy generated $77.34M in revenue, accounting 57.48% of the company's total revenue, up 296.70% year-over-year. Collaboration revenue generated $57.21M in revenue, accounting 42.52% of the company's total revenue, up 17.58% year-over-year.

What is Theravance Biopharma’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Theravance Biopharma was YUPELRI Monotherapy. This segment made a revenue of $77.34M, representing 57.48% of the company's total revenue.